ABC 60mg / 3TC 30mg / DTG 5mg, disp. tab.
STD
DORAABLD6TD
Valid Article
HS Code:
300490
Last Updated on:
25/09/2024, 13:27:07
6.4.2.5 - Fixed-dose combinations of antiretroviral medicines
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR13
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
ABACAVIR (ABC)/ LAMIVUDINE (3TC)/ DOLUTEGRAVIR (DTG) paed
Full Name
Paediatric abacavir/ lamivudine/ dolutegravir (pALD) fixed-dose combination
- In the WHO list of Essential Medicines 2023 (ABC 120 mg / 3TC 30 mg + DTG [10 or 50 mg])
Therapeutic Action
Paediatric fixed-dose combination of three antiretrovirals (pALD):
- nucleotide reverse transcriptase inhibitors (NRTI) : abacavir (ABC) and lamivudine (3TC)
- Integrase strand transfer inhibitor (INSTI): dolutegravir (DTG)
Indications
HIV infection, according to dosage recommended by WHO.
First-line ART regimen for children at least 3 months of age and weighing 6 to 24.9 kg.
Instructions for use
Paediatric use only.
Tablets should be dispersed in water only and given orally once per day.
The fixed combination ABC 60 mg / 3TC 30 mg / DTG 5 mg replaces separate components ABC 120 mg / 3TC 60 mg + DTG 10 mg in children from 6 to < 25 kg.
Separate components ABC 120 mg / 3TC 60 mg + DTG 10 mg will still be used for children from 3 to 5.9 kg.
Storage
- Below 25ºC - Protect from humidity
- Keep the bottle tightly closed. Do not remove the desiccant.